Tuesday's U.S. midterm election resulted in political shifts of a magnitude unseen in the last 50 years. TGH Research Associate Alejandra Martinez and Senior Contributing Editor Katherine Leach-Kemon interviewed CFR's Bloomberg chair in global health, Thomas Bollyky, and Senior Fellows Prashant Yadav, Stephanie Psaki, and Yanzhong Huang about what the elections may mean for global health. The fellows also described the implications of voters' choices for domestic health policy and research.
Shifting to the topic of illicit drugs, Vital Strategies' Daliah Heller, vice president of Overdose Prevention Initiatives, and Ariella Rojhani, director of the Partnership for Healthy Cities, detail steps that city leaders in the United States, Brazil, and Greece are taking to counter risks from synthetic drugs. Cities' approaches include changing laws to broaden access to naloxone—a medication for reversing opioid overdoses—as well as streamlining services and securing housing for people experiencing homelessness.
The last two pieces explore issues that weighed on the U.S. electorate's mind as they cast their votes: the rising cost of health care and the Make America Healthy Again (MAHA) agenda. Joseph Dieleman, professor of health metrics sciences at the University of Washington's Institute for Health Metrics and Evaluation, spoke with TGH's Katherine Leach-Kemon about the reasons Americans are paying more for health care. Another piece, written by journalist Anika Nayak, looks at how Arkansas has been at the forefront of the MAHA movement to push non-evidence-based fertility treatments, which doctors worry could limit patients' access to science-backed methods including in vitro fertilization.
Until next week!—Katherine Leach-Kemon, Senior Contributing Editor, and Alejandra Martinez, Research Associate
